Elanco Animal Health Inc (ELAN) Form 10-Q — Nov 6, 2026
Elanco Animal Health reported Q3 2026 revenue of $1,265 million, up 11% year over year, and swung to net income of $18 million ($0.04 diluted EPS) from a $34 million loss in Q3 2025. Nine-month net income rose 193% to $129 million on revenue of $4,004 million, up 12%, with gross margin expanding to 56.9% on favorable pricing and mix. Pet Health led growth at +14%, driven by Zenrelia and Credelio Quattro adoption. The company completed the $241 million acquisition of AHV International in April 2026, contributed ~$22 million of revenue, and continues its 2025 Restructuring Plan targeting ~$25 million of savings in 2026 and ~$60 million in 2027.
Key figures
- Eps
- 0.04
- Revenue
- 1265
- Net Income
- 18
- Total Debt
- 3449
- Revenue Yoy
- 11% (Q3); 12% nine months ($4,004M vs $3,571M)
- Total Assets
- 13340
- Cash Position
- 465
- Shares Outstanding
- 499827067
- Gross margin q3
- 56.9%
- Nine month net income
- 129
- Pet health q3 revenue
- 608
- Restructuring savings
- $25M in 2026, ~$60M in 2027
- Farm animal q3 revenue
- 631
- Ahv purchase consideration
- 241
- Operating cash flow nine months
- 506
- Blackstone future revenue liability
- 309
- Restructuring 2026 charges expected
- $25-30M
- Effective interest rate future revenue sale
- 18.4%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.